Morgan Stanley Forecasts Strong Price Appreciation for Phibro Animal Health (NASDAQ:PAHC) Stock

Phibro Animal Health (NASDAQ:PAHC) had its price objective lifted by analysts at Morgan Stanley from $20.00 to $25.00 in a research report issued on Tuesday,Benzinga reports. The firm currently has an “equal weight” rating on the stock. Morgan Stanley’s price objective suggests a potential upside of 17.54% from the company’s previous close.

A number of other research analysts have also recently weighed in on PAHC. Barclays boosted their target price on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a research note on Tuesday, November 12th. JPMorgan Chase & Co. assumed coverage on shares of Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price target on the stock. Bank of America boosted their price target on shares of Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Finally, StockNews.com lowered shares of Phibro Animal Health from a “strong-buy” rating to a “buy” rating in a research report on Friday, December 6th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $20.50.

Phibro Animal Health Stock Down 4.8 %

PAHC opened at $21.27 on Tuesday. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. The stock has a market cap of $861.50 million, a price-to-earnings ratio of 49.47, a PEG ratio of 0.58 and a beta of 0.51. Phibro Animal Health has a twelve month low of $10.03 and a twelve month high of $25.98. The company’s 50-day moving average price is $23.63 and its two-hundred day moving average price is $20.66.

Institutional Trading of Phibro Animal Health

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BNP Paribas Financial Markets increased its holdings in Phibro Animal Health by 3.1% during the 3rd quarter. BNP Paribas Financial Markets now owns 24,336 shares of the company’s stock worth $548,000 after acquiring an additional 729 shares during the period. CWM LLC increased its holdings in Phibro Animal Health by 89.8% during the 2nd quarter. CWM LLC now owns 2,188 shares of the company’s stock worth $37,000 after acquiring an additional 1,035 shares during the period. China Universal Asset Management Co. Ltd. increased its holdings in Phibro Animal Health by 63.7% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 3,912 shares of the company’s stock worth $88,000 after acquiring an additional 1,522 shares during the period. Public Sector Pension Investment Board increased its holdings in Phibro Animal Health by 6.1% during the 2nd quarter. Public Sector Pension Investment Board now owns 44,796 shares of the company’s stock worth $751,000 after acquiring an additional 2,583 shares during the period. Finally, Segall Bryant & Hamill LLC increased its holdings in Phibro Animal Health by 1.7% during the 3rd quarter. Segall Bryant & Hamill LLC now owns 174,569 shares of the company’s stock worth $3,931,000 after acquiring an additional 2,971 shares during the period. Institutional investors own 99.34% of the company’s stock.

Phibro Animal Health Company Profile

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.